Devonian Health Group Inc.
Devonian Health Group Inc.
Your view on DVHGF
Overview
What the company does, where it operates, and who runs it.
About Devonian Health Group Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Andre Boulet
- Headquarters
- 360, rue des Entrepreneurs, Québec, QC, CA
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Andre Boulet
- Headquarters
- 360, rue des Entrepreneurs, Québec, QC, CA
Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine, a Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis.
The company also develops Pantoprazole Magnesium for the treatment of gastric or duodenal ulcers; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics. In addition, it acquires drug and health product licenses; and distributes pharmaceutical products.
Devonian Health Group Inc. has a strategic alliance with CannTx Life Sciences Inc. for the development of cannabinoid-based pharmaceutical drugs. The company was incorporated in 2015 and is headquartered in Québec, Canada.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Devonian Health Group Inc., and the rating behind it. DVHGF last traded at $10.65; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Devonian Health Group Inc.. Starting points for Devonian Health Group Inc.: EPS -$2.17, beta 1.40 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Devonian Health Group Inc.. Devonian Health Group Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Devonian Health Group Inc.. Trailing twelve-month EPS for Devonian Health Group Inc. stands at -$2.17. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Devonian Health Group Inc.. Devonian Health Group Inc. has reported as a listed company since 2022. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Devonian Health Group Inc. valued side by side against its closest peers. Devonian Health Group Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Devonian Health Group Inc., and how their positions are changing. At a $29.5M market value, institutional positions materially move Devonian Health Group Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Devonian Health Group Inc. executives and directors. Shares of Devonian Health Group Inc. have traded between $4.27 and $10.80 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Devonian Health Group Inc.. Devonian Health Group Inc. is a $29.5M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Devonian Health Group Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Devonian Health Group Inc.. Coverage tracks Devonian Health Group Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.